First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas
Crossref DOI link: https://doi.org/10.1007/s12032-017-1076-1
Published Online: 2017-12-29
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Castelli, Roberto http://orcid.org/0000-0003-3976-7690
Bergamaschini, Luigi
Deliliers, Giorgio Lambertenghi
License valid from 2017-12-29